{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:44:53Z","timestamp":1771328693589,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03301-9","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:16:26Z","timestamp":1757340986000},"page":"5578-5599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe Disease"],"prefix":"10.1007","volume":"42","author":[{"given":"Mark E.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Proskorovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Guyot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pragya","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Pulikottil-Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lasair","family":"O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Pollissard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"3301_CR1","volume":"27","author":"KS Park","year":"2021","unstructured":"Park KS. Carrier frequency and predicted genetic prevalence of Pompe disease based on a general population database. Mol Genet Metab Rep. 2021;27: 100734.","journal-title":"Mol Genet Metab Rep"},{"key":"3301_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12883-017-0983-2","volume":"17","author":"B Schoser","year":"2017","unstructured":"Schoser B, Bilder DA, Dimmock D, Gupta D, James ES, Prasad S. The humanistic burden of Pompe disease: are there still unmet needs? A systematic review. BMC Neurol. 2017;17:202.","journal-title":"BMC Neurol"},{"key":"3301_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ymthe.2004.09.017","volume":"11","author":"N Raben","year":"2005","unstructured":"Raben N, Fukuda T, Gilbert AL, et al. Replacing acid \u03b1-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther. 2005;11:48\u201356.","journal-title":"Mol Ther"},{"issue":"751\u201376","key":"3301_CR4","first-page":"ix","volume":"32","author":"M Dasouki","year":"2014","unstructured":"Dasouki M, Jawdat O, Almadhoun O, et al. Pompe disease: literature review and case series. Neurol Clin. 2014;32(751\u201376):ix.","journal-title":"Neurol Clin"},{"key":"3301_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/mus.21393","volume":"40","author":"American Association of Neuromuscular & Electrodiagnostic Medicine","year":"2009","unstructured":"American Association of Neuromuscular & Electrodiagnostic Medicine. Diagnostic criteria for late-onset (childhood and adult) Pompe disease. Muscle Nerve. 2009;40:149\u201360.","journal-title":"Muscle Nerve"},{"key":"3301_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ajmg.c.31322","volume":"160","author":"A Sch\u00fcller","year":"2012","unstructured":"Sch\u00fcller A, Wenninger S, Strigl-Pill N, Schoser B. Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet Part C Semin Med Genet. 2012;160:80\u20138.","journal-title":"Am J Med Genet Part C Semin Med Genet"},{"key":"3301_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mus.22329","volume":"45","author":"EJ Cupler","year":"2012","unstructured":"Cupler EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45:319\u201333.","journal-title":"Muscle Nerve"},{"key":"3301_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1750-1172-6-34","volume":"6","author":"D G\u00fcng\u00f6r","year":"2011","unstructured":"G\u00fcng\u00f6r D, de Vries JM, Hop WC, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis. 2011;6:34.","journal-title":"Orphanet J Rare Dis"},{"key":"3301_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1750-1172-8-49","volume":"8","author":"D G\u00fcng\u00f6r","year":"2013","unstructured":"G\u00fcng\u00f6r D, Kruijshaar ME, Plug I, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis. 2013;8:49.","journal-title":"Orphanet J Rare Dis"},{"key":"3301_CR10","first-page":"78","volume":"32","author":"A Toscano","year":"2013","unstructured":"Toscano A, Montagnese F, Musumeci O. Early is better? A new algorithm for early diagnosis in late onset Pompe disease (LOPD). Acta Myol. 2013;32:78\u201381.","journal-title":"Acta Myol"},{"key":"3301_CR11","unstructured":"USFDA. Drug Approval Package-Myozyme. 2006. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/125141s000_MyozymeTOC.cfm."},{"key":"3301_CR12","unstructured":"European Medicines Agency. European Medicines Agency-Nexviadyme (avalglucosidase alfa). 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexviadyme. Accessed 8 Apr 2024."},{"issue":"Suppl 1","key":"3301_CR13","first-page":"114","volume":"12","author":"PS Kishnani","year":"2014","unstructured":"Kishnani PS, Beckemeyer AA. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. Pediatr Endocrinol Rev. 2014;12(Suppl 1):114\u201324.","journal-title":"Pediatr Endocrinol Rev"},{"key":"3301_CR14","first-page":"e1756","volume":"93","author":"L Harlaar","year":"2019","unstructured":"Harlaar L, Hogrel JY, Perniconi B, et al. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurol. 2019;93:e1756\u201367.","journal-title":"Neurol"},{"key":"3301_CR15","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","volume":"20","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera J, Kishnani PS, Kushlaf H, et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): A phase 3, randomised, multicentre trial. Lancet Neurol. 2021;20:1012\u201326.","journal-title":"Lancet Neurol"},{"key":"3301_CR16","unstructured":"USFDA. Nexviazyme-FDA label 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761194s000lbl.pdf."},{"key":"3301_CR17","doi-asserted-by":"crossref","unstructured":"Mellerio JE. The challenges of clinical trials in rare diseases: Blackwell Publishing Ltd Oxford, UK; 2022.","DOI":"10.1111\/bjd.21686"},{"key":"3301_CR18","unstructured":"Sanofi. Press Release: Nexviadyme\u00ae (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease. 2022. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-06-28-05-30-00-2469979. Accessed Mar 2024."},{"key":"3301_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/22143602251332829","author":"KI Berger","year":"2025","unstructured":"Berger KI, Ivanescu C, Msihid J, et al. Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: lessons learned from the COMET study in Pompe disease. J Neuromusc Dis. 2025. https:\/\/doi.org\/10.1177\/22143602251332829.","journal-title":"J Neuromusc Dis"},{"key":"3301_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16223","volume":"31","author":"A Lika","year":"2024","unstructured":"Lika A, Andrinopoulou ER, van der Beek N, Rizopoulos D, van der Ploeg AT, Kruijshaar ME. Establishing how much improvement in lung function and distance walked is clinically important for adult patients with Pompe disease. Eur J Neurol. 2024;31: e16223.","journal-title":"Eur J Neurol"},{"key":"3301_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s40265-023-01886-5","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair HA. Cipaglucosidase alfa: First approval. Drugs. 2023;83:739\u201345.","journal-title":"Drugs"},{"key":"3301_CR22","unstructured":"FDA. POMBILITI (cipaglucosidase alfa-atga) Prescribing Information Sep 2023. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761204s000lbl.pdf."},{"key":"3301_CR23","unstructured":"European Medicines Agency. SUMMARY OF PRODUCT CHARACTERISTICS Pombiliti. 2023. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20230320158375\/anx_158375_en.pdf."},{"key":"3301_CR24","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","volume":"20","author":"B Schoser","year":"2021","unstructured":"Schoser B, Roberts M, Byrne BJ, et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol. 2021;20:1027\u201337.","journal-title":"Lancet Neurol"},{"key":"3301_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/2229-3485.140550","volume":"5","author":"N Bhatnagar","year":"2014","unstructured":"Bhatnagar N, Lakshmi PV, Jeyashree K. Multiple treatment and indirect treatment comparisons: an overview of network meta-analysis. Perspect Clin Res. 2014;5:154\u20138.","journal-title":"Perspect Clin Res"},{"key":"3301_CR26","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1002\/sim.8759","volume":"39","author":"DM Phillippo","year":"2020","unstructured":"Phillippo DM, Dias S, Ades AE, Welton NJ. Assessing the performance of population adjustment methods for anchored indirect comparisons: a simulation study. Stat Med. 2020;39:4885\u2013911.","journal-title":"Stat Med"},{"key":"3301_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38:200\u201311.","journal-title":"Med Decis Making"},{"key":"3301_CR28","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE: NICE Decision Support Unit; 2016."},{"key":"3301_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2165\/11537420-000000000-00000","volume":"28","author":"JJ Caro","year":"2010","unstructured":"Caro JJ, Ishak KJ. No head-to-head trial? Simulate the missing arms. Pharmacoeconomics. 2010;28:957\u201367.","journal-title":"Pharmacoeconomics"},{"key":"3301_CR30","first-page":"e536","volume":"99","author":"MM Dimachkie","year":"2022","unstructured":"Dimachkie MM, Barohn RJ, Byrne B, et al. Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset Pompe Disease. Neurol. 2022;99:e536\u201348.","journal-title":"Neurol"},{"key":"3301_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"LDM Pena","year":"2019","unstructured":"Pena LDM, Barohn RJ, Byrne BJ, et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-na\u00efve and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscul Disord. 2019;29:167\u201386.","journal-title":"Neuromuscul Disord"},{"key":"3301_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","volume":"80","author":"PS Kishnani","year":"2023","unstructured":"Kishnani PS, Diaz-Manera J, Toscano A, et al. Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial. JAMA Neurol. 2023;80:558\u201367.","journal-title":"JAMA Neurol"},{"key":"3301_CR33","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/j.ymgme.2018.12.212","volume":"126","author":"P Kishnani","year":"2019","unstructured":"Kishnani P, Schoser B, Bratkovic D, et al. First-in-human study of advanced and targeted acid \u03b1-glucosidase (AT-GAA) (ATB200\/AT2221) in patients with Pompe disease: preliminary functional assessment results from the ATB200-02 trial. Mol Genet Metab. 2019;126:S86.","journal-title":"Mol Genet Metab"},{"key":"3301_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1750-1172-7-73","volume":"7","author":"JM de Vries","year":"2012","unstructured":"de Vries JM, van der Beek NA, Hop WC, et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis. 2012;7:73.","journal-title":"Orphanet J Rare Dis"},{"key":"3301_CR35","unstructured":"In\u00e1cio P. Lung function reduced in LOPD despite long-term myozyme use. Pompe Disease News. 2021."},{"key":"3301_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ymgme.2016.01.013","volume":"117","author":"KM Stepien","year":"2016","unstructured":"Stepien KM, Hendriksz CJ, Roberts M, Sharma R. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5 years. Mol Genet Metab. 2016;117:413\u20138.","journal-title":"Mol Genet Metab"},{"key":"3301_CR37","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1007\/s00415-020-09936-8","volume":"267","author":"DW Stockton","year":"2020","unstructured":"Stockton DW, Kishnani P, van der Ploeg A, et al. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start. J Neurol. 2020;267:3038\u201353.","journal-title":"J Neurol"},{"key":"3301_CR38","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s00415-023-12096-0","volume":"271","author":"BJ Byrne","year":"2023","unstructured":"Byrne BJ, Schoser B, Kishnani PS, et al. Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I\/II study (ATB200-02). J Neurol. 2023;271:1787\u2013801.","journal-title":"J Neurol"},{"key":"3301_CR39","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1007\/s00415-019-09401-1","volume":"266","author":"KI Berger","year":"2019","unstructured":"Berger KI, Kanters S, Jansen JP, et al. Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis. J Neurol. 2019;266:2312\u201321.","journal-title":"J Neurol"},{"key":"3301_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/1750-1172-8-160","volume":"8","author":"R Lachmann","year":"2013","unstructured":"Lachmann R, Schoser B. The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis. 2013;8:160.","journal-title":"Orphanet J Rare Dis"},{"key":"3301_CR41","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683\u201391.","journal-title":"J Clin Epidemiol"},{"key":"3301_CR42","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/rssa.12579","volume":"183","author":"DM Phillippo","year":"2020","unstructured":"Phillippo DM, Dias S, Ades AE, et al. Multilevel network meta-regression for population-adjusted treatment comparisons. J R Stat Soc Ser A Stat Soc. 2020;183:1189\u2013210.","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"3301_CR43","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40273-015-0271-1","volume":"33","author":"KJ Ishak","year":"2015","unstructured":"Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics. 2015;33:537\u201349.","journal-title":"Pharmacoeconomics"},{"key":"3301_CR44","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0045","volume":"13","author":"S Shohet","year":"2024","unstructured":"Shohet S, Hummel N, Fu S, et al. Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data. J Comp Eff Res. 2024;13: e240045.","journal-title":"J Comp Eff Res"},{"key":"3301_CR45","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/sim.8139","volume":"38","author":"J Leahy","year":"2019","unstructured":"Leahy J, Thom H, Jansen JP, et al. Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: assessing the impact. Stat Med. 2019;38:2505\u201323.","journal-title":"Stat Med"},{"key":"3301_CR46","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/S0960-8966(22)00680-0","volume":"32","author":"S Fu","year":"2022","unstructured":"Fu S, Hummel N, Mozaffar T, et al. Indirect treatment comparison of three enzyme replacement treatments for late-onset Pompe disease: a network meta-analysis with patient-level and aggregate data (LSVP.19). Neuromusc Disorders. 2022;32:S154\u2013202.","journal-title":"Neuromusc Disorders"},{"key":"3301_CR47","unstructured":"Products CfOM. Orphan Maintenance Assessment Report\u2014Pombiliti (Recombinant human acid alpha-glucosidase) EU\/3\/18\/2000. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/pombiliti-epar-public-assessment-report_en.pdf."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03301-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03301-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03301-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:02:46Z","timestamp":1762030966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03301-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3301"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03301-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark E. Roberts is part of the Advisory Boards for Amicus Therapeutics, BioMarin, Sanofi and Spark Therapeutics. Irina Proskorovsky and Pragya Shukla are employees of Evidera and may hold shares in the company. Patricia Guyot, Nathan Thibault, Alaa Hamed, Lasair O\u2019Callaghan and Laurence Pollissard are employees of Sanofi and may hold stocks and\/or stock options in the company. Ruth Pulikottil-Jacob was an employee of Sanofi at the time of study conduct. Her current affiliation, unrelated to this work is Cepheid UK, High Wycombe, UK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocols for the studies included in the ITC were reviewed and approved by appropriate ethics committees and\/or institutional review boards and conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation Guidelines for Good Clinical Practice. Written informed consent was obtained from participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}